News

The new approval grants BD the ability to move forward with a new device aimed at repairing abdominal hernias.

The therapy was shown in a 94-patient trial to reduce porphyria attacks by 70% versus placebo.

The FDA gives a green light to MiSight, a single use, contact lens to slow the progression of nearsightedness in children.

Crizanlizumab is the first ever drug approved to reduce vaso-occlusive crises in patients with the rare blood disease.

In the pivotal assessment, three-quarters of patients who received cefiderocol had resolution of symptoms and eradication of the bacteria 1 week after completing treatment, versus 54.6% of patients who received an alternative antibiotic.

The IL-5 inhibitor has shown significant benefits for HES in a phase 3 pivotal trial, and is now being considered for regulatory submission.

Listen in to the audio transcript of a policy- and public health-based discussion on mental health stigma from a panel of experts.

How the greatest use of the drug class may just come in the most severe cases.

The rate of pediatric and adolescent patients adhering to 30-day corticosteroid refill schedules increased by nearly 50 percentage points.

A new survey shows more than 60% of adult patients with peanut allergy do not feel confident in managing their condition, despite taking preventive measures.

The ALK-Abello expert details the positive findings from the vast, novel assessment of Ragwitek in children with ragweed allergic rhinitis with or without conjunctivitis.

New findings show Viaskin Peanut provided significant improvements to HRQL over placebo in a pair of its clinical trials.

The US FDA has approved lusaptercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular blood red blood cell transfusions.

A new survey shows patients and family members prefer telemedicine physician visits as much as they do in-person appointments—or even more so than the latter.

A 20-patient survey evidences the benefit of subcutaneous immunotherapy among patients aged 9-18 years old.

New findings from the phase 3 PALISADE and ARTEMIS trials show more than half of treated patients could tolerate 1000 mg peanut protein in a post-care food challenge.

A new international study has found patients with spinal cord injuries were 7 times more likely to be fatigued and more than 3 times more likely to have sleep apnea than their able-bodied counterparts.

A new 7-year analysis from the University of Cambridge is shining light on the underlying causes of the "weekend effect" in emergency departments.

A new study from Northwestern is highlighting the disparities in postpartum pain management received by non-Hispanic black and Hispanic women compared to their white counterparts.

A new analysis of nearly 500,000 Chinese patients found insomnia symptoms were associated with an increased risk of cardiovascular and cerebrovascular disease.

The pivotal phase 3 findings are the largest to assess a systemic pediatric atopic dermatitis treatment, to date.

A new study has found use of ketamine for treatment of acute or chronic pain does not increase risk for hepatotoxicity or other adverse drug events, as some previous research has suggested.

Despite a higher genetic risk, investigators link physical activity with decreased odds for developing depression.

A new meta-analysis of more than 31 randomized trials found fish oil supplements—specifically omega-3, alpha-linolenic acid, and total polyunsaturated fats—had little to no impact on the treatment or prevention of depression or anxiety symptoms.

A recent meta-analysis of more than 200,000 patients found running once a week was associated with a decreased risk of death from cancer, cardiovascular disease, and all-cause mortality.

New data shows that selective serotonin reuptake inhibitors reduce obsessive-compulsive symptoms for children and adolescents with autism spectrum disorders.

The new vaccine is expected to be available for the 2020-2021 influenza season.

A new study from Duke University suggests combining weight loss counseling to group medical visits was noninferior to typical medication treatment for lowing HbA1c in diabetic patients.

A new study from the National Center for Global Health and Medicine in Japan has found thiazide use in diabetics with well-controlled blood pressure led to an increased risk of MACE, particularly stroke.

RedHill Biopharma Ltd. has received FDA approval for RHB-105 (Talicia) for the treatment of Helicobacter pylori in adults.